|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Sharing Real-World Experiences with New Rett Syndrome Therapies
Target Audience
The educational design of this activity addresses the needs of neurologists, pediatric neurologists, and specialty NP/PAs involved in the treatment of patients with Rett syndrome.
Program Overview
Integrating newer agents for the treatment of Rett syndrome into clinical practice can be challenging, particularly in community settings. In this activity, an expert panel will convene featuring a neurologist from an International Rett Syndrome Foundation (IRSF)-designated cente... |
|
|
Identifying Needs and Opportunities to Improve Clinical Outcomes in the Identification, Characterization, and Management of Low-Grade Serous Ovarian Cancer
Target Audience
This activity is designed to meet the educational needs of oncologists, obstetrician/gynecologists, gastroenterologists, and primary care physicians to ensure confidence in the diagnosis, characterization, and management of low-grade serous ovarian cancer, including through enrollment in ongoing clinical trials.
Program Overview
This enduring educational activity will provide insight into evidence-based approaches for clinical and pathological assessment of patients with d... |
|
|
Teaming Up to Treat Rett Syndrome: The Importance of Fostering a Multidisciplinary Approach to Patient Care
Target Audience
The educational design of this activity addresses the needs of neurologists, pediatric neurologists and specialty NP/PAs involved in the treatment of patients with Rett syndrome.
Program Overview
With newer therapies now available for the treatment of Rett syndrome, it is essential that the challenges of managing patients with rare diseases, such as Rett syndrome in resource-poor areas or “care deserts” be addressed.
Join a neurologist and a gastroenterologist from ... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Alpha-1 Antitrypsin Deficiency (AATD) Case Studies and Expert Perspectives: Screening, Diagnosis, and Augmentation Therapy
Target Audience
The intended audience for this activity is pulmonologists, allergists, hepatologists, gastroenterologists, respiratory therapists, and other health care providers who screen and manage patients with alpha-1 antitrypsin deficiency (AATD).
Program Overview
Alpha-1 antitrypsin deficiency (AATD) is one of the most prevalent genetic diseases. It is an uncommonly diagnosed, potentially life-threatening genetic disorder that predisposes individuals to lung and/or liver disease. I... |
|
|
Simple Steps for Improving the Quality of Healthcare for Patients with Chronic Idiopathic Constipation
To ensure your patients with chronic idiopathic constipation (CIC) receive timely, appropriate interventions and the best possible care, clinicians need to better distinguish CIC from similar conditions. In addition, working together, clinicians and patients can make better choices among the many treatment options through shared decision-making (SDM) strategies to help achieve treatment goals.
This digital format provides a brief questionnaire to capture your current practices and delivers... |
|